TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06723964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP505
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP505
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP505
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP505
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP505
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP505
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP505
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP505
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP505
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP505
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.
Study: NCT06277804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004 in Combination With Cyclophosphamide and Fludarabine
Description: LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004 in Combination With Cyclophosphamide and Fludarabine
Description: LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable
Study: NCT04982666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Food, Plant-Based Diet
Description: This diet is focused on nutritional needs with natural, minimally-processed plant foods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP Diet
Description: An elimination diet of fermentable, oligosaccharides, disaccharides, monosaccharides and polyols
Study: NCT06557889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Cisplatin/Carboplatin + 5-FU
Description: * 4 cycles of combination treatment: 4 cycles of pembrolizumab (200 mg IV on Day 1 of each 3-week cycle) in combination with chemotherapy with platinum salts (cisplatin (100 mg/m2 IV on Day 1 of each 3-week cycle) or carboplatin (AUC 5 IV on Day 1 of each 3-week cycle), at the investigator's choice) and 5-FU (1000 mg/m2/day IV continuous from Day 1-4 of each 3-week cycle).~* Maintenance phase: pembrolizumab is continued as monotherapy for up to 24 months of treatment in total (from the first injection of cycle 1).
Study: NCT06270199

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions
Description: 3 doses of 5 million MSC will be administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions
Description: 6 doses of 5 million MSC will be administered
Study: NCT06172777

Intervention type: DIAGNOSTIC_TEST
Intervention: suspected asthma
Description: enrollment 200 asthma patients

Intervention type: DIAGNOSTIC_TEST
Intervention: suspected COPD
Description: enrollment 200 COPD patients

Intervention type: DIAGNOSTIC_TEST
Intervention: confirmed asthma
Description: enrollment 200 patients

Intervention type: DIAGNOSTIC_TEST
Intervention: confirmed COPD
Description: enrollment 200 patients
Study: NCT05583331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery will be performed as per local practice and standard guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery will be performed as per local practice and standard guidelines.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Vitrectomy will be performed as per local practice and standard guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Description: Vitrectomy will be performed as per local practice and standard guidelines.
Study: NCT05945979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A power supplement with biotin
Description: A power dietary supplement containing aminoacids and vitamins
Study: NCT06724939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-adhesive bulk-fill resin composite
Description: surefil one self-adhesive bulk-fill composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-adhesive bulk-fill resin composite
Description: surefil one self-adhesive bulk-fill composite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-adhesive bulk-fill resin composite
Description: surefil one self-adhesive bulk-fill composite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-adhesive bulk-fill resin composite
Description: surefil one self-adhesive bulk-fill composite
Study: NCT06452888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support system.
Description: The clinical decision support system includes evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures. Patients in the intervention group will receive the organizational management based on the guidelines and conduct intervention management for patients with actue ischemic stroke. The clinical decision system will classify the patients into risk factors, automatically generate treatment measures according to the guidelines, in order to standardize the treatment of physicians. Such as the management of complications after stroke, the treatment of antiplatelet, anticoagulation, antihypertensive and hypoglycemic.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: no intervention
Description: No intervention indicated that the physicians among control hospital provide routine
Study: NCT05888272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress managment
Description: The Doing What Matters in Times of Stress self-help manual materials and lay helper scripts utilized in the study are rooted in the principles of Acceptance and Commitment Therapy (ACT). They are designed to improve psychological flexibility which refers to an individual's ability to adapt to changing situations, reallocate mental resources, shift perspectives, and balance competing priorities. The ACT approach teaches individuals how to manage challenging thoughts and emotions through mindfulness techniques, while also guiding them to live in alignment with their personal values.
Study: NCT06585436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal
Description: removal of all cavity caries except last layer related to the pulp

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal
Description: removal of all cavity caries except last layer related to the pulp
Study: NCT05028569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BOTOX
Description: Intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injection
Study: NCT05650281

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION
Study: NCT06478563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111 (formulation D)
Description: Participants will receive NNC0487-0111 (formulation D) tablet once daily.
Study: NCT06585436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal
Description: removal of all cavity caries except last layer related to the pulp

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal
Description: removal of all cavity caries except last layer related to the pulp

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal
Description: removal of all cavity caries except last layer related to the pulp

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal
Description: removal of all cavity caries except last layer related to the pulp
Study: NCT05978947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZyMōt Multi 850µL device
Description: The ZyMōt Multi 850µL device is a laboratory tool designed for use in assisted reproductive technology (ART) procedures such as intrauterine insemination (IUI) and in vitro fertilization (IVF). It is a sperm preparation device that uses a proprietary patented technology to isolate and select motile sperm from semen samples for use in ART procedures.
Study: NCT06478563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111 (formulation D)
Description: Participants will receive NNC0487-0111 (formulation D) tablet once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNC0487-0111 (formulation C)
Description: Participants will receive NNC0487-0111 (formulation C) tablet once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNC0487-0111 (formulation C)
Description: Participants will receive NNC0487-0111 (formulation C) tablet once daily.
Study: NCT05254483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UNICEF kid power program immediately
Description: The intervention will be delivered via the UNICEF Kid Power website (https://www.unicefkidpower.org/) and any screened device such as a computer, smartphone, smart TV or an electronic tablet can be used to watch the videos and perform the assigned physical activity.~Participants will self-select activities 5 days a week. The participants will have the choice to undertake the physical activity in bouts and accumulate it over the course of the day.~To promote adherence to intervention, a weekly email with reminder to perform the physical activity will be sent to parents. In addition, research-based articles on the importance of physical activity and behavior change in children will also be emailed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UNICEF kid power program for waitlist control
Description: The wait-list control group will perform physical activity as usual and will only receive a weekly email on the importance of healthy dietary habits in children. The intervention will last 12 weeks. At the end of the study, the wait-list control group will be offered the UNICEF Kid Power intervention for a duration of 12-weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraph Accelerometer
Description: The participants will be mailed accelerometers and instructed to wear for 7 consecutive days during their waking hours, prior to the start of intervention. The mail containing the accelerometer will accompany pictorial instructions, explaining in detail the correct way of wearing it.
Study: NCT05122364

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation and telecoaching
Description: Language Sessions online and coaching parents online to improve language and social outcomes of their children
Study: NCT05254483

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiGraph Accelerometer
Description: The participants will be mailed accelerometers and instructed to wear for 7 consecutive days during their waking hours, prior to the start of intervention. The mail containing the accelerometer will accompany pictorial instructions, explaining in detail the correct way of wearing it.
Study: NCT06546046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG monitoring by telemetry device and patch-type ECG monitor at the same time
Description: The patient undergoes electrocardiogram monitoring simultaneously through a telemetry device and a patch-type electrocardiograph.
Study: NCT05122364

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Face to Face Language sessions
Description: Language sessions Face to Face at sohag phoniatrics unit
Study: NCT05658705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15-min supine time
Description: The length of preoperative supine time before AVS was 15 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2-hour supine time
Description: The length of preoperative supine time before AVS was 2 hours.
Study: NCT06379776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education through a 3D model
Description: Training through a 3D model of the spine fractures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education through a traditional pedagogical support
Description: Training through a traditional pedagogical support
Study: NCT06225687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Application
Description: The researcher will conduct daily measurements of gastric residual volume (GRV) and abdominal circumference, listen to bowel sounds, and assess distension from the first day of enteral nutrition initiation. Additionally, they will record the frequency of vomiting/defecation. Subsequently, a 15-minute hot application will be applied to the abdominal/lumbar region.
Study: NCT04737018

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fugl-Meyer Assessment (FMA)
Description: assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fugl-Meyer Assessment (FMA)
Description: assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Medical Research Concil (MRC)
Description: evaluation of muscular strength score from 0 to 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Research Concil (MRC)
Description: evaluation of muscular strength score from 0 to 5

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 2 Minute Walk Test (2MWT)
Description: Assess functional walking and aerobic abilities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 Minute Walk Test (2MWT)
Description: Assess functional walking and aerobic abilities

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Timed Up & Go Test
Description: measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timed Up & Go Test
Description: measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Modified Ashworth Scale
Description: score from 0 to 4 evaluation of spasticity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale
Description: score from 0 to 4 evaluation of spasticity

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Postural Assessment Scale for Stroke
Description: score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Assessment Scale for Stroke
Description: score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: posturographic recording
Description: analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: posturographic recording
Description: analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform
Study: NCT05927753

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deseyne Daily Disposable Contact Lens (Test Device)
Description: Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deseyne Daily Disposable Contact Lens (Test Device)
Description: Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.
Study: NCT06305533

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER disinfection
Description: In test group 1, the diode Laser will be used to disinfect the inner layer of the pockets and thus reducing the microbial load. Diode laser (Biolase, EpicX, BIOLASE, Inc, USA) settings will be as follows: wavelength: 940nm; power: 1W; 300μm uninitiated fibers; continuous radiation mode; and energy level: 80 J/s. The laser fibers then will be inserted into the pockets in such a way that they will be in contact with the soft tissue wall of the pockets and parallel to the root surface and then will be moved to the apical surface through a horizontal sweeping motion (1mm/s) while remaining in contact with the soft tissue wall of the pockets.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: the second test group will receive additional adjunctive aPDT using a ICG photosensitizer activated with diode laser. In details, pockets will be irrigated by a syringe loaded with an ICG photosensitizer solution (Verdye, Diagnostic green, Germany) at a concentration of 5mg/ml. The ICG solution will be allowed to stay in the pockets for 2min, and washing out excess solution from the pockets before laser irradiation. Afterwards, a 300μm bulb optical fibre of the 810nm diode laser unit (QuickLase, United Kingdom) set at 300mw in pulsed mode (100ms ON/100ms OFF) will be inserted along the pocket and activated for 30s with continuous vertical movements from the bottom of the pocket to the gingival margin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Root surface debridement
Description: For all groups, sites with initial PPD 4-6 mm will be treated with RSD using area specific (Graecy) curettes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root surface debridement
Description: For all groups, sites with initial PPD 4-6 mm will be treated with RSD using area specific (Graecy) curettes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root surface debridement
Description: For all groups, sites with initial PPD 4-6 mm will be treated with RSD using area specific (Graecy) curettes.
Study: NCT05703893

Intervention type: DIAGNOSTIC_TEST
Intervention: Supine resting (REST) and active standing (STAND)
Description: Analysis of baroreflex sensitivity

Intervention type: DIAGNOSTIC_TEST
Intervention: Supine resting (REST) and active standing (STAND)
Description: Analysis of baroreflex sensitivity
Study: NCT05932446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC.
Study: NCT05648695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Non-invasive Neuromodulation
Description: The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
Study: NCT05868031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alternative teaching methods
Description: This study aimed to explore the potential benefits of alternative teaching methods in anatomy education, as well as to investigate the effectiveness of traditional lecture-based education in comparison. By examining the outcomes of these different approaches, we hope to understand better how students can best learn and retain knowledge in this field.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alternative teaching methods
Description: This study aimed to explore the potential benefits of alternative teaching methods in anatomy education, as well as to investigate the effectiveness of traditional lecture-based education in comparison. By examining the outcomes of these different approaches, we hope to understand better how students can best learn and retain knowledge in this field.
Study: NCT04737018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration program
Description: a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
Study: NCT05584007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin Only Product in Oral Dose Form
Description: Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flucloxacillin Only Product in Oral Dose Form
Description: Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Only Product in Oral Dose Form
Description: Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
Study: NCT06336603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Winlevi (clascoterone) 1% & Adapalene 0.3% gel
Description: Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD)